
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by function and pathway, with brief roles:<br><br>**a. Endothelial identity / vascular development**<br><br>- **CLDN5** ‚Äì Tight junction protein claudin-5; canonical marker of brain microvascular endothelial cells and blood‚Äìbrain barrier (BBB) integrity.  <br>- **VWF** ‚Äì von Willebrand factor; Weibel‚ÄìPalade body component, classic endothelial marker (especially venous/large vessel, but also present in CNS endothelium).  <br>- **CD34** ‚Äì Sialomucin expressed on vascular endothelial cells and hematopoietic progenitors; strong pan-endothelial marker in brain.  <br>- **KDR (VEGFR2/FLK1)** ‚Äì Major VEGF receptor driving endothelial proliferation and angiogenesis.  <br>- **FLT1 (VEGFR1)** ‚Äì VEGF receptor; modulates VEGF signaling, often enriched in endothelial cells.  <br>- **FLT4 (VEGFR3)** ‚Äì VEGF receptor associated with lymphatic endothelium and some specialized vascular beds; also seen in angiogenic/venous endothelium.  <br>- **TIE1** ‚Äì Endothelial receptor tyrosine kinase; involved in vascular remodeling and angiogenesis.  <br>- **EMCN (endomucin)** ‚Äì Sialomucin expressed on endothelial cells, especially microvascular; widely used as a CNS endothelial marker.  <br>- **ROBO4** ‚Äì Endothelial-specific roundabout receptor; stabilizes vasculature and regulates angiogenesis.  <br>- **ECSCR** ‚Äì Endothelial cell-specific chemotaxis regulator; enriched in endothelial cells.  <br>- **NOSTRIN** ‚Äì Nitric oxide synthase trafficker; regulates eNOS in endothelial cells.  <br>- **CCM2L** ‚Äì Cerebral cavernous malformation 2-like; involved in endothelial junction stability and vascular integrity.  <br>- **SOX7, SOX17** ‚Äì Endothelial/hemogenic endothelium transcription factors; key in vascular development and arterial specification.  <br>- **BCL6B** ‚Äì Transcription factor implicated in endothelial cell function and angiogenesis.  <br>- **ECSCR, EXOC3L2** ‚Äì Both enriched in endothelial cells; EXOC3L2 is associated with exocyst complex and endothelial migration.  <br>- **ECSCR, EMCN, ROBO4, CLDN5, CD34, VWF** together form a very strong endothelial signature.<br><br>**b. Angiogenesis / tip/stalk cell and arterial‚Äìvenous specification**<br><br>- **DLL4** ‚Äì Notch ligand highly enriched in arterial and tip endothelial cells; central to tip/stalk cell selection and arterial specification.  <br>- **NOTCH4** ‚Äì Endothelial Notch receptor; mediates DLL4‚ÄìNotch signaling in arterial and angiogenic endothelium.  <br>- **SELE (E-selectin)** ‚Äì Inducible adhesion molecule on activated endothelium; often upregulated in inflamed or angiogenic vessels.  <br>- **RAMP3** ‚Äì Receptor activity-modifying protein; modulates adrenomedullin/calcitonin receptor-like receptor signaling, important in vascular tone and angiogenesis.  <br>- **APLNR (APJ receptor)** ‚Äì Apelin receptor; strongly associated with angiogenic and tip endothelial cells, especially in CNS vasculature.  <br>- **PLVAP** ‚Äì Plasmalemma vesicle-associated protein; diaphragms of fenestrae and caveolae; enriched in permeable/angiogenic endothelium and at BBB ‚Äúleaky‚Äù sites.  <br>- **MMRN2** ‚Äì Multimerin 2; extracellular matrix protein secreted by endothelial cells, associated with angiogenic vasculature.  <br>- **NPR1** ‚Äì Natriuretic peptide receptor 1; regulates vascular tone and permeability.  <br>- **STC1** ‚Äì Stanniocalcin 1; secreted glycoprotein involved in angiogenesis and hypoxia responses.  <br>- **MYRIP** ‚Äì Myosin VIIA and Rab interacting protein; involved in secretory granule trafficking (e.g., Weibel‚ÄìPalade bodies) in endothelial cells.<br><br>**c. Vascular permeability / BBB vs non-BBB features**<br><br>- **CLDN5, ROBO4, EMCN, NOSTRIN, CCM2L** ‚Äì Support a BBB-like, stabilized endothelium.  <br>- **PLVAP, ACKR1, SELE, VWF, MMRN2** ‚Äì More typical of permeable, post-capillary venule/venous or angiogenic endothelium rather than the tight BBB capillary phenotype.  <br>- **CA4** ‚Äì Carbonic anhydrase IV; in brain, strongly enriched in capillary endothelial cells and involved in CO‚ÇÇ/HCO‚ÇÉ‚Åª transport and pH regulation; a hallmark of brain capillary endothelium in several scRNA-seq atlases.  <br>- **GPIHBP1** ‚Äì Glycosylphosphatidylinositol-anchored HDL-binding protein 1; involved in lipoprotein lipase transport; enriched in capillary endothelium of certain vascular beds.<br><br>**d. Chemokines / adhesion / immune interaction**<br><br>- **ACKR1 (DARC)** ‚Äì Atypical chemokine receptor 1; classic marker of venular/post-capillary endothelial cells that bind chemokines and facilitate leukocyte trafficking.  <br>- **CCL14** ‚Äì Chemokine ligand; may reflect inflammatory/immune-interacting endothelium.  <br>- **SELE** ‚Äì As above, inducible adhesion molecule for leukocyte rolling.  <br>- **FCN3** ‚Äì Ficolin-3; complement pathway component, sometimes expressed by endothelial cells in immune-active vascular beds.<br><br>**e. Other signaling / receptors**<br><br>- **EDNRB** ‚Äì Endothelin receptor type B; expressed in vascular smooth muscle and some endothelial cells; in brain, also in pericytes and some glia, but here co-occurs with strong endothelial markers.  <br>- **ADGRL4 (ELTD1)** ‚Äì Adhesion GPCR; highly enriched in endothelial cells, especially in angiogenic/brain tumor vasculature; robust endothelial marker.  <br>- **CLEC14A** ‚Äì C-type lectin domain family 14 member A; very specific for endothelial cells, particularly tip/angiogenic endothelium.  <br>- **TIE1, KDR, FLT1, FLT4, APLNR, EDNRB, NPR1** ‚Äì Together define a highly signaling-competent, angiogenic endothelial phenotype.<br><br>**f. Transcriptional regulators / others**<br><br>- **SOX7, SOX17, BCL6B** ‚Äì Endothelial/vascular transcription factors, often enriched in arterial/angiogenic endothelium.  <br>- **MYCT1** ‚Äì MYC target 1; may reflect proliferative/activated state.  <br>- **ZNF366** ‚Äì Nuclear receptor corepressor; not cell-type specific but may modulate transcriptional programs.  <br>- **SRARP** ‚Äì Steroid receptor-associated and ARP-like protein; less specific, but reported in endothelial contexts.  <br>- **USHPB1, FAM110D, TM4SF18, PCAT19, LINC01235, CXorf36, TMEM233** ‚Äì Less characterized, but several are reported as endothelial-enriched in bulk and single-cell datasets.<br><br>**g. Neuronal-looking outlier**<br><br>- **GABRD** ‚Äì Œ¥ subunit of GABA-A receptor; typically neuronal. Its presence here is likely ambient RNA, doublet contamination, or misassignment, given the overwhelmingly endothelial signature.<br><br>---<br><br>2. Key cell-type markers (tissue-level)<br><br>From the above, the dominant cell-type‚Äìdefining markers are:<br><br>- **Canonical endothelial markers**: CLDN5, VWF, CD34, EMCN, ROBO4, ECSCR, KDR, FLT1, FLT4, TIE1, CLEC14A, ADGRL4, PLVAP, ACKR1, MMRN2, GPIHBP1, CA4, NOSTRIN, CCM2L, EXOC3L2.  <br>- **Brain microvascular/BBB-associated**: CLDN5, CA4, ROBO4, EMCN, NOSTRIN, CCM2L, APLNR, SOX17.  <br>- **Arterial/angiogenic endothelial markers**: DLL4, NOTCH4, SOX7, SOX17, APLNR, CLEC14A, ADGRL4, RAMP3, SELE, PLVAP, MMRN2.  <br>- **Venous/post-capillary venule markers**: ACKR1, SELE, VWF, PLVAP, FCN3, some FLT4 expression.<br><br>No astrocyte (GFAP, AQP4, SLC1A2), oligodendrocyte (MBP, PLP1, MOG), microglial (CX3CR1, P2RY12, AIF1), neuronal (RBFOX3, SNAP25, SLC17A7, GAD1/2), or pericyte/smooth muscle (PDGFRB, RGS5, ACTA2, TAGLN) markers are present at high rank. The profile is unambiguously endothelial.<br><br>---<br><br>3. Cross-referencing with scRNA-seq atlases and literature<br><br>Cross-checking with major human brain scRNA-seq references:<br><br>- **Lake et al., 2018; Hodge et al., 2019; Tasic et al. (mouse); Saunders et al., 2018; Vanlandewijck et al., 2018; Sunkin et al.** and more recent human atlases (e.g., **Zhang et al., 2016; Habib et al., 2017; Li et al., 2021**):  <br>  - **CLDN5, VWF, CD34, EMCN, ROBO4, KDR, FLT1, TIE1, SOX17, SOX7, APLNR, CA4, GPIHBP1, NOSTRIN, CLEC14A, ADGRL4** are all strongly enriched in endothelial clusters.  <br>  - **CA4** and **GPIHBP1** are particularly characteristic of **capillary endothelial cells** in brain (Vanlandewijck et al., Nature 2018; human/mouse vascular atlas).  <br>  - **DLL4, NOTCH4, SOX17, SOX7** are enriched in **arterial and tip endothelial** subclusters.  <br>  - **ACKR1, SELE, PLVAP, VWF** are enriched in **venous/post-capillary venule** endothelial cells and in more permeable segments of the vasculature.  <br>  - **ADGRL4 (ELTD1), CLEC14A, MMRN2, RAMP3, APLNR** are repeatedly reported as **angiogenic/tip cell markers** in tumor and developmental vasculature, including brain.<br><br>Thus, the marker set matches **brain vascular endothelial cells**, with a bias toward **angiogenic and/or venous/post-capillary** phenotypes, but also including **capillary markers (CA4, GPIHBP1)** and **arterial/tip markers (DLL4, SOX17, NOTCH4)**.<br><br>---<br><br>4. Most probable general cell type<br><br>Given:<br><br>- Strong, coherent endothelial signature (CLDN5, VWF, CD34, EMCN, ROBO4, KDR, FLT1, TIE1, CLEC14A, ADGRL4, etc.).  <br>- Presence of brain-specific microvascular markers (CA4, GPIHBP1, NOSTRIN, CCM2L).  <br>- Absence of markers for neurons, glia, pericytes, or smooth muscle.<br><br>**Most probable general cell type:  <br>Brain vascular endothelial cells (microvascular endothelium).**<br><br>---<br><br>5. Top 3 most probable endothelial subtypes (ranked)<br><br>Within brain endothelial cells, major subtypes typically include: arterial, capillary, venous/post-capillary venule, and specialized angiogenic/tip or activated states. This cluster shows a mixture, but the ranked markers give clues.<br><br>### 1) Angiogenic / tip‚Äìstalk brain endothelial cells (most likely)<br><br>Evidence:<br><br>- **Strong angiogenic/tip markers**:  <br>  - **CLEC14A** (top-ranked) ‚Äì highly specific for tip/angiogenic endothelium.  <br>  - **ADGRL4 (ELTD1)** ‚Äì robustly associated with angiogenic endothelium, especially in CNS and tumors.  <br>  - **DLL4, NOTCH4** ‚Äì canonical tip/stalk and arterial specification pathway; DLL4 is a hallmark of tip cells.  <br>  - **APLNR** ‚Äì enriched in angiogenic/tip endothelial cells in brain vasculature.  <br>  - **RAMP3, STC1, MMRN2, PLVAP** ‚Äì all associated with activated/angiogenic or remodeling endothelium.  <br>- **Transcriptional program**:  <br>  - **SOX7, SOX17, BCL6B** ‚Äì consistent with an arterial/angiogenic endothelial transcriptional state.  <br>- **Functional context**:  <br>  - Combination of **VEGF receptors (KDR, FLT1, FLT4)**, **Notch signaling (DLL4, NOTCH4)**, and **adhesion/chemokine receptors (SELE, ACKR1)** suggests active remodeling and interaction with immune cells, typical of angiogenic or reactive vasculature.<br><br>Given the prominence and rank of CLEC14A, ADGRL4, DLL4, APLNR, and PLVAP, an **angiogenic/tip‚Äìstalk brain endothelial** identity is the best fit.<br><br>### 2) Venous / post-capillary venule endothelial cells<br><br>Evidence:<br><br>- **ACKR1 (DARC)** ‚Äì classic marker of post-capillary venules and venous endothelium, especially in brain and other tissues.  <br>- **SELE** ‚Äì inducible on activated venular endothelium; mediates leukocyte rolling.  <br>- **VWF, PLVAP, FCN3** ‚Äì more strongly expressed in venous/post-capillary segments and permeable vessels than in tight BBB capillaries.  <br>- **RAMP3, EDNRB, NPR1** ‚Äì consistent with regulation of vascular tone and permeability, often more prominent in venous/venular beds.<br><br>The co-expression of **ACKR1 + SELE + PLVAP + VWF** is highly suggestive of **post-capillary venule/venous endothelial cells**, likely in an activated state. However, the strong tip/angiogenic markers push the primary annotation toward an angiogenic phenotype that may span multiple segments.<br><br>### 3) Capillary brain endothelial cells (CA4+/GPIHBP1+)<br><br>Evidence:<br><br>- **CA4** ‚Äì one of the most specific markers of **brain capillary endothelial cells** in multiple atlases.  <br>- **GPIHBP1** ‚Äì enriched in capillary endothelium in several tissues, including CNS microvasculature.  <br>- **CLDN5, EMCN, ROBO4, NOSTRIN, CCM2L** ‚Äì all consistent with a stabilized, BBB-like capillary phenotype.<br><br>However:<br><br>- The presence of **PLVAP, ACKR1, SELE, VWF** and strong angiogenic markers (CLEC14A, ADGRL4, DLL4, APLNR) is atypical for a purely quiescent BBB capillary cluster.  <br>- This suggests either:  <br>  - A **mixed capillary‚Äìvenous‚Äìangiogenic** endothelial cluster, or  <br>  - A capillary-derived endothelium undergoing **angiogenic activation** and partial loss of strict BBB features.<br><br>Given the ranked list, capillary markers are present but not as dominant as the angiogenic/tip and venous activation markers.<br><br>---<br><br>**Most likely specific subtype annotation**<br><br>Integrating all evidence:<br><br>- Dominant high-ranking markers: **CLEC14A, ADGRL4, DLL4, PLVAP, APLNR, RAMP3, MMRN2, SOX7, SOX17, NOTCH4** ‚Üí strong **angiogenic/tip‚Äìstalk** signature.  <br>- Co-expression of **ACKR1, SELE, VWF, PLVAP** ‚Üí **venous/post-capillary** and **immune-interacting** phenotype.  <br>- Presence of **CA4, GPIHBP1, CLDN5, EMCN, ROBO4** ‚Üí **brain microvascular** (capillary/BBB-lineage) context.<br><br>Thus, the most coherent interpretation is:<br><br>> **General cell type:** Brain vascular endothelial cells  <br>> **Most likely subtype:** Angiogenic / tip‚Äìstalk brain microvascular endothelial cells, with a venous/post-capillary bias (ACKR1‚Å∫, SELE‚Å∫, PLVAP‚Å∫) rather than purely quiescent BBB capillaries.<br><br>If you need a concise label suitable for an atlas:<br><br>- **Primary label:** ‚ÄúEndothelial cells ‚Äì angiogenic brain microvascular (CLEC14A‚Å∫/ADGRL4‚Å∫/DLL4‚Å∫)‚Äù  <br>- **Alternative label:** ‚ÄúBrain endothelial ‚Äì venous/post-capillary, angiogenic (ACKR1‚Å∫/PLVAP‚Å∫/DLL4‚Å∫)‚Äù<br><br>---<br><br>6. Concise summary<br><br>- The marker set is unequivocally **endothelial**, with strong brain microvascular features (CLDN5, CA4, EMCN, ROBO4, NOSTRIN, CCM2L).  <br>- High expression of **CLEC14A, ADGRL4, DLL4, NOTCH4, APLNR, PLVAP, MMRN2, RAMP3, SOX7, SOX17** indicates an **angiogenic/tip‚Äìstalk endothelial** program.  <br>- Co-expression of **ACKR1, SELE, VWF, PLVAP, FCN3** suggests a **venous/post-capillary venule** and immune-interacting phenotype rather than purely quiescent capillary BBB endothelium.  <br>- Capillary markers (CA4, GPIHBP1) indicate that these cells are part of the **brain microvascular network**, likely undergoing remodeling.<br><br>**Final interpretation:**  <br>This cluster represents **angiogenic brain microvascular endothelial cells**, most consistent with **tip‚Äìstalk / activated venous‚Äìpost-capillary endothelial cells** in human brain.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Brain vascular endothelial cells (microvascular endothelium)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Angiogenic / tip‚Äìstalk brain endothelial cells</li><li>Venous / post-capillary venule endothelial cells</li><li>Capillary brain endothelial cells (CA4+/GPIHBP1+)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Mixed capillary‚Äìvenous‚Äìangiogenic endothelial cluster</li><li>Tip‚Äìstalk / activated venous‚Äìpost-capillary brain endothelial cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    